person-years of observation (460 person-years receiving efavirenz). No baseline differences in depression or suicidal ideation were found between patients ever exposed to efavirenz and those never exposed to efavirenz and receiving nevirapine (P > 0.80 for both). Of 305 participants ever-exposed to efavirenz, 61 (20.0%) and 19 (6.2%) had depression and suicidal ideation, respectively, on at least 1 follow-up visit, compared with 125 (32.1%) and 47 (12.1%) of the 389 who received nevirapine. In adjusted GEE models, efavirenz use was associated with decreased odds of depression compared with nevirapine use (adjusted odds ratio, 0.62 [95% CI, 0.40 to 0.96]) and was not significantly associated with suicidal ideation (adjusted odds ratio, 0.61 [CI, 0.30 to 1.25]). Time-to-event and marginal structural models yielded similar estimates.
Limitation: Nonrandom assignment to treatment and substantial differences between the efavirenz and nevirapine groups.
Conclusion:
No evidence was found that use of efavirenz in firstline ART increased the risk for depression or suicidal ideation compared with nevirapine use among PLHIV in Uganda. 
Primary Funding

E
favirenz, an HIV nonnucleoside reverse transcriptase inhibitor, is still commonly used in both lowand high-income countries (1) . Concern has been increasing regarding serious neuropsychiatric adverse events, such as depression and suicidality, with efavirenz use (2, 3) . A pooled analysis of data from 4 AIDS Clinical Trial Group studies showed an association between efavirenz use and an increased hazard of suicidality (2) , although such an association was not replicated by subsequent observational cohort studies (4 -7) . Nonetheless, in light of these data on suicidality, as well as concerns regarding the low barrier to resistance of efavirenz compared with newer agents, the U.S. Department of Health and Human Services removed efavirenz as a recommended first-line agent for HIV treatment (8).
However, the World Health Organization continues to recommend efavirenz as a key component of first-line antiretroviral therapy (ART) regimens in sub-Saharan Africa (9). However, few data exist concerning neuropsychiatric effects of efavirenz use in the region, where more than 12 million persons living with HIV (PLHIV) are estimated to be receiving ART (10) . This question is especially important given the elevated prevalence of depression among PLHIV (11) and its contribution to poor HIV treatment outcomes (12, 13) . The objective of this analysis was to examine the association between efavirenz use and the risk for depression and suicidal ideation in a cohort of PLHIV receiving ART in rural Uganda in order to provide safety data regarding efavirenz use in the region.
Mbarara Regional Referral Hospital HIV clinic at the time of ART initiation. To be eligible, patients at the clinic had to be aged at least 18 years, ART-naive, and living within 60 km (about 37.3 miles) of the clinic.
Study participants were observed 4 times per year until June 2011, when visits decreased to 3 times a year. Study visits occurred adjacent to the HIV clinic. At each visit, participants had blood drawn for CD4 + T-lymphocyte cell counts and HIV-1 RNA viral load testing and completed structured interviews to assess for probable depression, suicidal ideation, alcohol use, and self-reported health status. Pregnancy also was de- termined by self-report until December 2011, when we began collecting urine for ␤-human chorionic gonadotrophin testing. For the purpose of this analysis, we excluded patients who did not start ART (n = 47), were not receiving efavirenz-or nevirapine-based therapy at any recorded follow-up visit (n = 1), had their baseline assessment for probable depression more than 3 days after ART initiation (n = 7), did not have at least 1 follow-up assessment for probable depression (n = 6), or lacked covariate data for follow-up visits (n = 7) (Appendix Figure, available at Annals.org).
Study Definitions
Outcomes
Our outcomes of interest were probable depression and suicidal ideation. Probable depression was measured with an adapted version of the 15-item depression subscale of the Hopkins Symptom Checklist, which we validated previously among PLHIV in Uganda (14 -18) . This adapted version includes a 16th item ("feeling like I don't care about my health") (19) . A participant was considered to have probable depression if his or her mean score on the items was greater than 1.75 (19, 20) . Suicidal ideation in the past week was assessed with the question "Do you have thoughts about ending your life?" measured on a 4-point Likert-type scale. A participant was considered to have suicidal ideation if he or she endorsed any amount of suicidal ideation on this item ("a little," "quite a bit," or "extremely" vs. "not at all").
Exposure
Our primary exposure of interest was time-varying use of efavirenz, defined as use during the past 7 days and in at least 60 of the past 90 days before a study visit. Our referent group comprised participants who used nevirapine, defined as not meeting criteria for efavirenz use and having any nevirapine use in the last 90 days before a study visit. We excluded any study visits in which a participant was receiving neither efavirenznor nevirapine-based therapy (for example, he or she was receiving a protease inhibitor) at the time of the visit (41 study visits [1.1%]); 1 participant was excluded from the analysis because this patient was receiving a protease inhibitor at all recorded follow-up study visits. For visits before participants completed 90 days of ART, exposure to efavirenz or nevirapine was defined as use during the past 7 days. Participants self-reported ART regimens and durations, and in instances in which the ART regimen was not valid (for example, the participant reported a monotherapy regimen), ART data from the HIV clinic were used instead. Missing ART regimen data were imputed for 4510 (1.1%) of 399 484 study days (Supplement [Methods] , available at Annals.org).
Confounding Variables
We adjusted for several time-varying demographic covariates, including age, marital status, educational attainment, and household asset ownership. Sex and year of study enrollment were also included in the models as time-fixed covariates. The asset ownership index was derived by applying the method of principal component analysis to 25 binary variables pertaining to household assets and housing characteristics, as suggested by Filmer and Pritchett (21) . The first component was extracted and used to define the asset ownership index, which was categorized into quintiles of relative household wealth. Year of enrollment was de- + T-lymphocyte count, viral suppression, antiretroviral therapy duration, health status, and heavy drinking) and time-independent covariates (sex, year of enrollment, probable depression at enrollment, suicidal ideation at enrollment, and tuberculosis co-infection).
¶ In the Cox model, EFV use was treated as a time-varying exposure and adjusted for the following baseline, time-independent covariates: age, sex, marital status, educational attainment, household asset ownership, CD4 + T-lymphocyte count, log 10 viral load, antiretroviral therapy duration, health status, heavy drinking, year of enrollment, probable depression, suicidal ideation, and tuberculosis co-infection. ** See the Methods section of the Supplement (available at Annals.org) for details on model specification.
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We adjusted for 3 baseline, time-fixed clinical variables: probable depression at enrollment, suicidal ideation at enrollment, and tuberculosis co-infection. We also adjusted for the following time-varying clinical variables: CD4 + T-lymphocyte cell count, viral suppression, ART duration, health status, and heavy drinking. Tuberculosis co-infection was ascertained in participants who self-reported tuberculosis or who were concurrently registered in the electronic database of the Mbarara Hospital tuberculosis ward. The ascertainment process consisted of an infectious disease physician's review of participants' clinical and laboratory records up until February 2013 (Supplement [Methods]). Viral suppression was defined as an undetectable viral load, which varied by assay type and decreased from 400 to 20 copies/mL as the study progressed. Duration of ART was measured in cumulative weeks since ART initiation. Health status was measured by the physical health summary score from the Medical Outcome Survey-HIV questionnaire and was categorized into quartiles (22) . Heavy drinking was determined by the 3-item consumption subset of the Alcohol Use Disorders Identification Test (23). Pregnancy was determined by selfreport or positive results on urine ␤-human chorionic gonadotrophin testing. Pregnancy was not adjusted for in models but served as a stratification variable in sensitivity analyses restricted to women.
Loss to Follow-up and Missing Visits
For our primary analysis, we restricted estimation to the first 2 years of treatment, the period during which efavirenz is most commonly associated with neuropsychiatric symptoms (24) . This period also corresponds to a window in which nearly all study participants had complete followup. We considered participants lost to follow-up if they withdrew from the study before 2 years or if their last study visit was earlier than 550 days from the date of ART initiation, except in the case of death. The 550-day threshold was selected because it was the time point after which 1 more study visit was expected during the first 2 years of treatment.
We performed an investigation after each death by reviewing the medical record and interviewing the patient's medical team or family (if death occurred outside a health facility) at the time of death. We recorded the cause of death as suicide, not suicide, or unknown. Nonsuicide deaths were censored at time of death.
Statistical Analysis
We characterized the distributions of variables at baseline and compared them between participants who met criteria for efavirenz exposure in 1 or more follow-up visits (ever-efavirenz users) and those who did not meet criteria in any follow-up visit during the first 2 years (only-nevirapine users). Differences in continuous and categorical variables at baseline were tested by using the Wilcoxon rank-sum and Pearson 2 tests, respectively. For our primary model, we fit generalized estimating equation (GEE) logistic regression models with an exchangeable correlation matrix for both depression and suicidal ideation, restricted to follow-up visits the first 2 years after ART initiation, with time-varying efavirenz exposure and adjustment for time-updated demographic and both baseline and time-updated clinical covariates. We calculated absolute risk reductions for our outcomes on the basis of the GEE model via the average adjusted prediction method and associated 95% CIs via the delta method. Next, we fit Cox proportional hazards regression models, using time to first visit with depression or suicidal ideation as the outcome of interest. We accounted for time-varying exposure and adjusted for time-fixed, baseline covariates to estimate differences in time to depression and time to suicidal ideation by efavirenz use. For this model, we substituted the viral suppression covariate with the log 10 of the baseline viral load. Participants were right censored at their last visit before 2 years. We plotted cumulative incidence curves using the Kaplan-Meier method and performed log-rank tests of equality between efavirenz and nevirapine users, accounting for time-varying exposure. We also calculated crude inci- Depression, Suicidal Ideation, and Efavirenz in Uganda ORIGINAL RESEARCH dence rate differences in first-ever events between the 2 groups. In subgroup analyses, we fit GEE models stratified by each covariate and plotted estimates of the association between efavirenz use and probable depression and suicidal ideation in forest plots. We interrogated the robustness of our primary and secondary models with several sensitivity analyses, including construction of a marginal structural model (described in the Supplement [Methods]). Sensitivity analyses accounting for loss to follow-up and missing visits imputed outcomes as positive and then as negative for suicidal ideation and probable depression at the last follow-up visit and at missing visits. Finally, following methods proposed by VanderWeele and Ding (25), we performed an E-value analysis. We sought to determine the minimum strength of association, on the risk ratio scale, that an unobserved confounder would require to have both the exposure and outcome, (conditional on the measured covariates), to move an estimate to a certain risk ratio or the upper limit of a CI to encapsulate that risk ratio. We used a reference risk ratio of 1.27, which represents the lower 95% confidence limit for the association between efavirenz use and suicidal ideation or attempted or completed suicide estimated in a previous analysis (2) .
All statistical analyses were performed by using Stata, version 14.2 (StataCorp).
Ethical Approval
Ethical approval for study procedures was obtained by the Partners Human Research Committee at Massachusetts General Hospital; the Committee on Human Research at University of California, San Francisco; and the Research Ethical Committee at Mbarara University of Science and Technology. The study was cleared by the Uganda National Council of Science and Technology. All participants gave written informed consent.
Role of the Funding Source
The National Institutes of Health (NIH), Harvard and San Francisco Centers for AIDS Research, and Doris Duke Charitable Foundation funded this study. The funding sources had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; or preparation or submission of the manuscript for publication.
RESULTS
Participant Characteristics and Study Follow-up
Of 762 PLHIV who completed an enrollment study visit, 694 met the inclusion criteria (Appendix Figure) and contributed a total of 3854 follow-up study visits During the observation period, 17 participants (2.4%) died and 53 (7.6%) were lost to follow-up. Of the 17 deaths, the cause of death was not suicide in 16 and was unknown in 1. Table 1 summarizes participant characteristics at enrollment. Between the ever-efavirenz (n = 305) and only-nevirapine (n = 389) groups, no difference was found in the proportion of participants with probable depression and suicidal ideation at enrollment (P > 0.80 for both). Ever-efavirenz users were more likely than only-nevirapine users to be enrolled later during observation and to have a higher CD4 + T-cell count at enrollment (2.31 vs. 1.51 × 10 9 cells/L). The median proportion of visits with viral suppression was similar in both groups (83% vs. 86%), as was the proportion of participants who died (2.0% vs. 2.8%). The proportion of missed visits was smaller (9.6% vs. 15.4%) and fewer participants were lost to follow-up (4.3% vs. 10.3%) in the ever-efavirenz versus the only-nevirapine group.
Efavirenz Use and Probable Depression
The crude incidence of first probable depression was 11.4 and 23.7 per 100 person-years for the efavirenz-and nevirapine-exposed groups, respectively (difference, Ϫ12.3 events per 100 person-years [95% CI, Ϫ17.4 to Ϫ7.3]) ( Table 2 ). In the adjusted GEE model, efavirenz use was associated with decreased odds of probable depression (adjusted odds ratio, 0. 
Efavirenz Use and Suicidal Ideation
The crude incidence of first suicidal ideation was 3.1 and 7.4 per 100 person-years for the efavirenz-and nevirapine-exposed groups, respectively (difference, Ϫ4.2 [CI, Ϫ6.8 to Ϫ1.5] events per 100 person-years) ( Table 2 ). In the adjusted GEE model, efavirenz use was not significantly associated with suicidal ideation (adjusted odds ratio, 0.61 [CI, 0.30 to 1.25]; P = 0.178), corresponding to an adjusted absolute risk difference of Ϫ0.91% (CI, Ϫ2.1% to 0.3% [P = 0.143]) for efavirenz compared with nevirapine use. Likewise, in the adjusted Cox proportional hazards regression model, efavirenz use was not significantly associated with the hazard of suicidal ideation (adjusted hazard ratio, 0.47 [CI, 0.21 to 1.07]; P = 0.072) (Figure 1) .
Sensitivity Analysis
Consistent with other models, in marginal structural models, efavirenz use was significantly associated with decreased odds of probable depression (weighted odds ratio, 0.42 [CI, 0.21 to 0.81]; P = 0.010) ( The relationship between efavirenz use and probable depression or suicidal ideation was consistent in most subgroup analyses (Figures 2 and 3) . Estimates for probable depression and suicidal ideation also On the basis of estimates from our primary GEE model, E-value analyses showed that an unobserved confounder would require a strength of association with both efavirenz use and probable depression of 3.51 on the risk ratio scale to move our point estimate for the association of efavirenz use and depression (0.62) to a risk ratio of 1.27; it would require a strength of association of 1.98 to move the upper limit of our 95% CI (0.96) to encapsulate the same risk ratio. For suicidal ideation, an unobserved confounder would require a strength of association of 3.58 to move the point estimate to the specified risk ratio and 1.14 to move the 95% CI to encapsulate the same risk ratio. E-values at other thresholds and for other models are presented in Appendix Table 3 (available at Annals .org).
DISCUSSION
We found no evidence that efavirenz use was associated with an increased risk for probable depression or suicidal ideation among PLHIV initiating ART in rural Uganda. Our estimates unexpectedly showed that efavirenz use was associated with a decrease of approximately 40% in the odds of probable depression as well as a decrease in the hazard of time to first probable depression. These associations were robust to many sensitivity analyses and were corroborated by a marginal structural model accounting for potential timevarying confounding affected by previous treatment in cases in which efavirenz was withdrawn in patients with these symptoms. Moreover, our effect sizes were largely consistent across several demographic and clinical subgroups. Of note, efavirenz was not associated with an increased risk for probable depression or suicidal ideation in participants with baseline probable depression. Our findings offer compelling data that efavirenz is a safe option for first-line therapy in the region. 
Cumulative Incidence
Participants excluded from other analyses because of missing covariate data are included in these figures, which do not adjust for covariates. The curves are based on current exposure to NVP and EFV. For example, participants were counted in the NVP group until they began EFV, at which point they were included in the EFV group. EFV = time-varying efavirenz exposure; NVP = time-varying nevirapine exposure.
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In a pooled analysis of trial data, Mollan and colleagues (2) found that, in contrast to our study, efavirenz use was associated with a 2-fold increased hazard of suicidality in participants initiating ART, with 62 total first suicidality events reported in 9916 personyears of observation. The study found an increase of 6.25 suicidality events per 1000 person-years with use of efavirenz compared with other agents. Genetic differences in drug metabolism between Africans and whites may partially explain the varied effects of efavirenz seen in these different populations. A recent study in Botswana found a high prevalence of the slowmetabolizing efavirenz phenotype and an unexpected association of this phenotype with a lower central nervous system toxicity score (26) . However, this effect was measured 1 month after ART initiation and was not seen at 6 months. Nevertheless, studies associating slower efavirenz clearance with greater central nervous system toxicity have been conducted predominantly in white participants (27, 28) , whereas studies in persons of African ancestry largely have found no association (29 -31) . Efavirenz also has been shown to interact with several neurotransmitter pathways, and host genetic modulation of these pathways may lead to different phenotypic effects (32, 33) .
Differences in comparator ART regimens among studies also may be partially responsible. In the study by Mollan and colleagues (2), protease inhibitors were the comparator agents in 82% of the efavirenz-free regimens, whereas we compared efavirenz with nevirapine. Outcome assessment methods also were notably different; we used the modified depression subscale of the Hopkins Symptom Checklist, a validated survey tool to query for depression and suicidal ideation directly, whereas Mollan and colleagues assessed suicidality retrospectively, via a combination of automated and in- 
EFV better Odds Ratio (95% CI) NVP better
Participants, n
Odds ratio estimates are from a multivariable-adjusted generalized estimating equations logistic regression model. ART = antiretroviral therapy; EFV = efavirenz; NVP = nevirapine; PHS = physical health summary; TB = tuberculosis. * Too few participants.
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Depression, Suicidal Ideation, and Efavirenz in Uganda person chart reviews. Finally, 3 of the 4 trials in the analysis by Mollan and colleagues were open label, making the study susceptible to ascertainment bias, particularly in a trial setting. Although our investigation was an unblinded cohort study, clinic physicians prescribed ART apart from the structured assessment of depression and suicidal ideation, which was conducted in separate offices by study staff. Observational studies in the United States published after the report by Mollan and colleagues also found no association between efavirenz use and suicidality, although most were limited by potential channeling bias or time-varying confounding (4 -7). One systematic review of 42 randomized trials found no difference in the risk for central nervous system adverse events or suicidal ideation with efavirenz use (34) . A single clinical trial in ART-experienced participants comparing efavirenz with a protease inhibitor-based regimen found no association between efavirenz use and depressive symptoms (35) . Likewise, a crosssectional study in Senegal did not identify a difference in crude prevalence of depressive symptom scores between efavirenz and protease inhibitor users (36) . In our analysis, we attempted to account for channeling bias with sensitivity analyses excluding the group of patients for whom efavirenz might have been preferentially prescribed (that is, participants with tuberculosis co-infection or those who were pregnant) or avoided (that is, those with baseline depression or suicidal ideation). We also fit a marginal structural model that accounted for both potential channeling bias and time-varying confounding. Moreover, in our cohort, neither baseline nor timeupdated probable depression or suicidal ideation predicted efavirenz use. This finding was not unexpected given the rarity of screening for depression or suicidal ideation in routine clinical practice in the region, where clin- Depression, Suicidal Ideation, and Efavirenz in Uganda ORIGINAL RESEARCH ics remain largely focused on providing ART and managing and preventing opportunistic infections. We recognize the potential for unobserved confounding to explain the estimated associations. We attempted to address this source of bias by using several types of models, model specifications, adjustment methods, and exposure definitions; all models resulted in similar effect size estimates. We also performed E-value analyses to show how strong an unobserved confounder would have to be to move our estimates to a risk ratio of 1.27 and our 95% CIs to encompass that ratio. Of note, E-value analyses account only for unmeasured confounding and do not address other forms of potential bias, such as selection bias, measurement error, and bias due to missing data. We identified substantial differences between ever-efavirenz and onlynevirapine users by year of ART initiation, which might have confounded the association between efavirenz use and our outcomes. To account for this, we adjusted for year of enrollment in our analyses; described crude incidence of depression and suicidal ideation by period; conducted adjusted stratified analyses by period; and performed tests to assess for differences in crude and adjusted associations of efavirenz with our outcomes over time, which were not significant. Another limitation was the use of a self-reported depression screen to measure our outcomes of interest. This screening instrument, however, was validated in our patient population (14 -18) and tends to be overly sensitive and not result in underreporting; we documented no suicides among the 17 deaths observed during follow-up. Receipt of ART regimen prescriptions also was self-reported and thus susceptible to reporter bias. Finally, because this study was observational, our findings should be corroborated by a well-designed randomized controlled trial.
In summary, we believe our study is the first to detect a statistically significant, unexpected inverse association between efavirenz use and depression. These data offer preliminary evidence of possible regional differences in efavirenz tolerability. Further work is needed to confirm these results, establish consistency in other subpopulations, and elucidate possible genetic or environmental factors that might account for regional differences in efavirenz tolerability. We look forward to results from the ADVANCE study (ClinicalTrials.gov: NCT03122262), which is randomly assigning patients in South Africa to receive efavirenz-or dolutegravir-based ART regimens, with a focus on safety and tolerability (37) , to add to our work and elucidate optimal HIV treatment options in the region. * Some EFV use is defined as a prescription for EFV in the previous 90 days but not meeting the criteria for EFV exposure (receipt of an EFV prescription in 60 of the previous 90 days and the 7 previous days). † Missing visits were filled in between observed visits for the 694 participants in the primary analysis. One missed visit was also added after the last recorded visit if the last recorded visit was >3.5 months before the end of the 2-year study. Exposure and covariate values for missing visits were imputed by using a last-observation-carried-forward approach. ‡ Defined as a participant whose last visit within 2 years was ≤550 days after ART initiation. § This sensitivity analysis was not done for the Cox model, because the analysis would be the same as that of the primary Cox model. ͉͉ ART duration was fit as a natural cubic spline with knots at the 5th, 25th, 50th, 75th, and 95th percentiles. ¶ The internalized AIDS-related stigma score (38) was defined as a continuous covariate (range, 0-6).
